Sanford Advisory Services LLC Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by on May 12th, 2023

Sanford Advisory Services LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,133 shares of the company’s stock after selling 161 shares during the quarter. Sanford Advisory Services LLC’s holdings in Johnson & Johnson were worth $907,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Nordwand Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth $785,273,000. Savant Capital LLC increased its holdings in Johnson & Johnson by 8,568.8% in the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after acquiring an additional 3,588,251 shares in the last quarter. Edmp Inc. increased its holdings in Johnson & Johnson by 17,222.9% in the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after acquiring an additional 3,204,658 shares in the last quarter. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. Finally, GQG Partners LLC increased its holdings in Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.4 %

NYSE JNJ opened at $160.99 on Friday. The firm’s 50-day moving average is $158.97 and its two-hundred day moving average is $166.83. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market capitalization of $418.37 billion, a P/E ratio of 33.68, a PEG ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the prior year, the company posted $2.67 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson’s dividend payout ratio is 94.56%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Morgan Stanley upped their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Raymond James dropped their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. Atlantic Securities dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Piper Sandler dropped their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.